Daniel Lindén

12PUBLICATIONS
110CO-AUTHORS
PharmacogenomicsMedical infection agents (incl. prions)Medical biochemistry - lipidsHypersonic propulsion and hypersonic aerothermodynamicsNanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 15, 2026
Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.

|Nov 28, 2024
Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis.

Daniel Lindén, Gregory Tesz, Rohit Loomba

|Jun 12, 2024
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).

Michele Vacca, Ioannis Kamzolas, Lea Mørch Harder

|Jun 06, 2024
PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein.

Scott M Johnson, Hanmei Bao, Cailin E McMahon

|May 09, 2024
Reply to: Technical challenges of studying the impact of plasma components on the efficacy of lipid nanoparticles for vaccine and therapeutic applications.

Kai Liu, Elisa Lázaro-Ibáñez, Michael Lerche

|Jul 06, 2023
Multiomics analysis of naturally efficacious lipid nanoparticle coronas reveals high-density lipoprotein is necessary for their function.

Kai Liu, Ralf Nilsson, Elisa Lázaro-Ibáñez

Pageof 2

Frequent Collaborators

2 joint publications

Kai Liu

2 joint publications

Alan Sabirsh

2 joint publications

Elisa Lázaro-Ibáñez

2 joint publications

Linnéa Bergenholm